Learn more Retail traders linked the upcoming AML readout with CEO Angelos Stergiou's Fox appearance. The speculation centers ...
SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid ...
Stocktwits on MSN
SLS stock hits July low as AML readout nears — retail bulls see 'stellar' hint in CEO's Fox appearance next week
CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.
SELLAS (SLS) stock jumps 12% as investors watch the Phase 3 REGAL AML trial, short interest, and squeeze risk.
Sellas Life Sciences Group Inc SLS shares are trading sharply higher by about 24% on Monday as the stock extends a breakout run that has traders focused on fresh highs and corporate updates. SELLAS ...
On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc.
View SELLAS Life Sciences Group, Inc. SLS stock quote prices, financial information, real-time forecasts, and company news from CNN.
Sellas Life Sciences stock faces downside risk ahead of REGAL Phase 3 data, and the valuation looks stretched. Click here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results